summary: This study tested Fingolimod, an oral immunomodulator, against placebo to reduce disease activity in 281 patients with RRMS, as measured by a reduction in gadolinium-enhancing lesions on MRI. Over a six month period and twelve month extension, the Fingolimod-treated groups had lower relapse rates and less gadolinium enhancement on MRI. There were a variety of adverse events associated with the treatment, including one case of encephalopathy.

authors: Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW.

source: N Engl J Med. 2006 Sep 14;355(11):1124-40.

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: